l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation

Neurobiology of Disease

Volumn 29, Issue 2, 2008, Pages 327-335

  Picconi, Barbara ^a   Paillé, Vincent ^a   Ghiglieri, Veronica ^a   Bagetta, Vincenza ^a   Barone, Ilaria ^a   Lindgren, Hanna S ^d   Bernardi, Giorgio ^a,b   Angela Cenci, M ^d   Calabresi, Paolo ^a,c  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

^d LUND UNIVERSITY   (Sweden)

Author keywords

Dyskinesia; Electrophysiology; Levodopa; Parkinson's disease; Striatum; Synaptic plasticity

Indexed keywords

DOPAMINE; LEVODOPA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DENERVATION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG MEGADOSE; DYSKINESIA; ELECTROPHYSIOLOGY; EXPERIMENTAL MODEL; INVOLUNTARY MOVEMENT; LONG TERM POTENTIATION; LOW DRUG DOSE; MALE; MOTOR DYSFUNCTION; NERVE CELL PLASTICITY; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RAT; RECORDING; SYNAPTIC DEPOTENTIATION; SYNAPTIC POTENTIAL;

ADRENERGIC AGENTS; ANIMALS; ANTIPARKINSON AGENTS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG INTERACTIONS; DYSKINESIA, DRUG-INDUCED; ELECTRIC STIMULATION; LEVODOPA; LONG-TERM POTENTIATION; LONG-TERM SYNAPTIC DEPRESSION; MALE; MOTOR ACTIVITY; NEURONS; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, WISTAR; TYROSINE 3-MONOOXYGENASE;

EID: 38149033506     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2007.10.001     Document Type: Article

References (56)

1. Calabresi P., Centonze D., and Bernardi G. Electrophysiology of dopamine in normal and denervated striatal neurons. Trends Neurosci. 23 (2000) S57-S63
2. Calabresi P., Centonze D., Gubellini P., Marfia G., Pisani A., Sancesario A., and Bernardi G. Synaptic transmission in the striatum: from plasticity to neurodegeneration. Prog. Neurobiol. 61 (2000) 231-265
3. Calabresi P., Giacomini P., Centonze D., and Bernardi G. Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity?. Ann. Neurol. 47 (2000) S60-S68 (discussion S68-69)
4. Calabresi P., Gubellini P., Centonze D., Picconi B., Bernardi G., Chergui K., Svenningsson P., Fienberg A.A., and Greengard P. Dopamine and cAMP-regulated phosphoprotein 32 kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity. J. Neurosci. 20 (2000) 8443-8451
5. Calabresi P., Maj R., Pisani A., Mercuri N., and Bernardi B. Long-term synaptic depression in the striatum: physiological and pharmacological characterization. J. Neurosci. 12 (1992) 4224-4233
6. Calabresi P., Pisani A., Mercuri N., and Bernardi B. Long-term potentiation in the striatum is unmasked by removing the voltage-dependent magnesium block of NMDA receptor channels. Eur. J. Neurosci. 4 (1992) 929-935
7. Calabresi P., Mercuri N., Sancesario B., and Bernardi G. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. Brain 116 Pt 2 (1993) 433-452
8. Calon F., Dridi M., Hornykiewicz O., Bedard P.J., Rajput A.H., and Di Paolo T. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 127 (2004) 1075-1084
9. Calon F., Grondin R., Morissette M., Goulet M., Blanchet P.J., Di Paolo T., and Bedard P.J. Molecular basis of levodopa-induced dyskinesias. Ann. Neurol. 47 (2000) S70-S78
10. Calon F., Hadj Tahar A., Blanchetw P.J., Morissette M., Grondin R., Goulet M., Doucet J.P., Robertson G.S., Nestler E., Di Paolo T., and Bedard P.J. Dopamine-receptor stimulation: biobehavioral and biochemical consequences. Trends Neurosci. 23 (2000) S92-S100
11. Cenci M.A. Dopamine dysregulation of movement control in l-DOPA-induced dyskinesia. Trends Neurosci. 30 (2007) 236-243
12. Cenci M.A., Lee C.S., and Bjorklund A. l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 10 (1998) 2694-2706
13. Cenci M.A., and Lundblad M. Post- versus presynaptic plasticity in l-DOPA-induced dyskinesia. J. Neurochem. 99 (2006) 381-392
14. Centonze D., Gubellini P., Picconi B., Calabresi P., Giacomini P., and Bernardi G. Unilateral dopamine denervation blocks corticostriatal LTP. J. Neurophysiol. 82 (1999) 3575-3579
15. Centonze D., Grande C., Saulle E., Martin A.B., Gubellini P., Pavon N., Pisani A., Bernardi G., Moratalla R., and Calabresi P. Distinct roles of D1 and D5 dopamine receptors in motor activity and striatal synaptic plasticity. J. Neurosci. 23 (2003) 8506-8512
16. Chen Y.L., Huang C.C., and Hsu K.S. Time-dependent reversal of long-term potentiation by low-frequency stimulation at the hippocampal mossy fiber-CA3 synapses. J. Neurosci. 21 (2001) 3705-3714
17. Day M., Wang Z., Ding J., An X., Ingham C.A., Shering A.F., Wokosin D., Ilijic E., Sun Z., Sampson A.R., Mugnaini E., Deutch A.Y., Sesack S.R., Arbuthnott G.W., and Surmeier D.J. Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat. Neurosci. 9 (2006) 251-259
18. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann. Neurol. 47 (2000) S2-S9 (discussion S9-11)
19. Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease?. J. Neurol. 252 Suppl 4 (2005) IV37-IV42
20. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., Olanow C.W., Tanner C., and Marek K. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 351 (2004) 2498-2508
21. Fujii S., Matsumoto M., Igarashi K., Kato H., and Mikoshiba K. Synaptic plasticity in hippocampal CA1 neurons of mice lacking type 1 inositol-1,4,5-trisphosphate receptors. Learn. Mem. 7 (2000) 312-320
22. Gardoni F., Picconi B., Ghiglieri V., Polli F., Bagetta V., Bernardi G., Cattabeni F., Di Luca M., and Calabresi P. A critical interaction between NR2B and MAGUK in l-DOPA induced dyskinesia. J. Neurosci. 26 (2006) 2914-2922
23. Golbe L.I. Young-onset Parkinson's disease: a clinical review. Neurology 41 (1991) 168-173
24. Graybiel A.M. Network-level neuroplasticity in cortico-basal ganglia pathways. Parkinsonism Relat. Disord. 10 (2004) 293-296
25. Henry B., Crossman A.R., and Brotchie J.M. Characterization of enhanced behavioral responses to l-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp. Neurol. 151 (1998) 334-342
26. Henry B., Crossman A.R., and Brotchie J.M. Effect of repeated l-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp. Neurol. 155 (1999) 204-220
27. Huang C.C., Liang Y.C., and Hsu K.S. Characterization of the mechanism underlying the reversal of long term potentiation by low frequency stimulation at hippocampal CA1 synapses. J. Biol. Chem. 276 (2001) 48108-48117
28. Iravani M.M., Costa S., Jackson M.J., Tel B.C., Cannizzaro C., Pearce R.K., and Jenner P. GDNF reverses priming for dyskinesia in MPTP-treated, l-DOPA-primed common marmosets. Eur. J. Neurosci. 13 (2001) 597-608
29. Jankovic J. Levodopa strengths and weaknesses. Neurology 58 (2002) S19-S32
30. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov. Disord. 20 Suppl 11 (2005) S11-S16
31. Jiang Z.G., and North R.A. Membrane properties and synaptic responses of rat striatal neurones in vitro. J. Physiol. 443 (1991) 533-553
32. Kerr J.N., and Wickens J.R. Dopamine D-1/D-5 receptor activation is required for long-term potentiation in the rat neostriatum in vitro. J. Neurophysiol. 85 (2001) 117-124
33. Kita T., Kita H., and Kitai S.T. Passive electrical membrane properties of rat neostriatal neurons in an in vitro slice preparation. Brain Res. 300 (1984) 129-139
34. Linazasoro G. New ideas on the origin of l-dopa-induced dyskinesias: age, genes and neural plasticity. Trends Pharmacol. Sci. 26 (2005) 391-397
35. Lindgren H.S., Rylander D., Ohlin K.E., Lundblad M., and Cenci M.A. The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with l-DOPA: relation to dose and route of administration. Behav. Brain Res. 177 (2007) 150-159
36. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., and Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 15 (2002) 120-132
37. Maratos E.C., Jackson M.J., Pearce R.K., and Jenner P. Antiparkinsonian activity and dyskinesia risk of ropinirole and l-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus). Mov. Disord. 16 (2001) 631-641
38. Marin C., Rodriguez-Oroz M.C., and Obeso J.A. Motor complications in Parkinson's disease and the clinical significance of rotational behavior in the rat: have we wasted our time?. Exp. Neurol. 197 (2006) 269-274
39. Marras C., Lang A., Krahn M., Tomlinson G., and Naglie G. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations. Mov. Disord. 19 (2004) 22-28
40. Morgan S.L., Coussens C.M., and Teyler T.J. Depotentiation of vdccLTP requires NMDAR activation. Neurobiol. Learn. Mem. 76 (2001) 229-238
41. Morgante F., Espay A.J., Gunraj C., Lang A.E., and Chen R. Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. Brain 129 (2006) 1059-1069
42. Olanow C.W., Obeso J.A., and Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol. 5 (2006) 677-687
43. Paillé V., Brachet P., and Damier P. Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease. Neuroreport 15 (2004) 561-564
44. Paxinos G., Watson C., Pennisi M., and Topple A. Bregma, lambda and the interaural midpoint in stereotaxic surgery with rats of different sex, strain and weight. J. Neurosci. Methods 13 (1985) 139-143
45. Picconi B., Centonze D., Hakansson K., Bernardi G., Greengard P., Fisone G., Cenci M.A., and Calabresi P. Loss of bidirectional striatal synaptic plasticity in l-DOPA-induced dyskinesia. Nat. Neurosci. 6 (2003) 501-506
46. Picconi B., Pisani A., Centonze D., Battaglia G., Storto M., Nicoletti F., Bernardi G., and Calabresi P. Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment. Brain 125 (2002) 2635-2645
47. Picconi B., Gardoni F., Centonze D., Mauceri D., Cenci M.A., Bernardi G., Calabresi P., and Di Luca M. Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism. J. Neurosci. 24 (2004) 5283-5291
48. Picconi B., Pisani A., Barone I., Bonsi P., Centonze D., Bernardi G., and Calabresi P. Pathological synaptic plasticity in the striatum: implications for Parkinson's disease. Neurotoxicology 26 (2005) 779-783
49. Riley D.E., and Lang A.E. The spectrum of levodopa-related fluctuations in Parkinson's disease. Neurology 43 (1993) 1459-1464
50. Ruberg M., Scherman D., Javoy-Agid F., and Agid Y. Dopamine denervation, age of onset, and Parkinson's disease. Neurology 45 (1995) 392
51. Sauer H., and Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59 (1994) 401-415
52. Schrag A., and Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 123 Pt 11 (2000) 2297-2305
53. Schwarting R.K., and Huston J.P. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog. Neurobiol. 50 (1996) 275-331
54. Vidailhet M., Bonnet A.M., Marconi R., Durif F., and Agid Y. The phenomenology of l-dopa-induced dyskinesias in Parkinson's disease. Mov. Disord. 14 Suppl 1 (1999) 13-18
55. Wolters E.C., Francot C., Bergmans P., Winogrodzka A., Booij J., Berendse H.W., and Stoof J.C. Preclinical (premotor) Parkinson's disease. J. Neurol. 247 Suppl 2 (2000) II103-II109
56. Zhang C., Steiner J.P., Hamilton G.S., Hicks T.P., and Poulter M.O. Regeneration of dopaminergic function in 6-hydroxydopamine-lesioned rats by neuroimmunophilin ligand treatment. J. Neurosci. 21 (2001) RC156